Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,881 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 76,204 · Balance 216,881 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 279,181 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 62,300 · Balance 279,181 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 183,248 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 95,933 · Balance 183,248 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 256,000 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2023 Filed Dec 19, 2023 22:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 254 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-042031 · wk-form4_1703026481.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,366 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| December 03, 2023 Filed Dec 21, 2023 20:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-042480 · wk-form4_1703191464.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,653 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 00:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 666 | $12.37 | $8,238.42 |
DisclosureSEC source: 0001628280-23-040672 · wk-form4_1701735246.xml · nonDerivative · entry 2 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,112 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 19, 2023 Filed Dec 5, 2023 00:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 298 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-040672 · wk-form4_1701735246.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,778 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 15:40 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 97 | $10.66 | $1,034.02 |
DisclosureSEC source: 0001628280-23-039095 · wk-form4_1700062841.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,480 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 08-09-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 05, 2023 Filed Nov 13, 2023 21:40 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-038652 · wk-form4_1699911624.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,577 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| October 22, 2023 Filed Oct 24, 2023 23:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-035025 · wk-form4_1698191090.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,244 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| October 08, 2023 Filed Oct 10, 2023 21:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 281 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-034199 · wk-form4_1696973109.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,871 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| September 24, 2023 Filed Oct 2, 2023 21:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-033502 · wk-form4_1696280531.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,590 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 20:57 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 539 | $12.70 | $6,845.30 |
DisclosureSEC source: 0001628280-23-032947 · wk-form4_1695675448.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,300 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 06-19-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 20:48 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 408 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-032090 · wk-form4_1694551695.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,839 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| August 27, 2023 Filed Aug 30, 2023 21:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 498 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-031006 · wk-form4_1693431531.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,431 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 21:51 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 585 | $10.99 | $6,429.15 |
DisclosureSEC source: 0001628280-23-030912 · wk-form4_1693345863.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,933 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 20:47 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 94 | $12.57 | $1,181.58 |
DisclosureSEC source: 0001628280-23-029683 · wk-form4_1692218830.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,518 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 08-09-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 20:36 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 541 | $23.41 | $12,664.81 |
DisclosureSEC source: 0001628280-23-023458 · wk-form4_1687811752.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,612 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 06-19-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 560 | $23.21 | $12,997.60 |
DisclosureSEC source: 0001437749-23-016545 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,153 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 16, 2023 Filed May 18, 2023 01:51 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 137 | $19.41 | $2,659.17 |
DisclosureSEC source: 0001437749-23-015001 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,713 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 08-09-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 22, 2023 Filed Mar 22, 2023 23:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 310 | $21.84 | $6,770.40 |
DisclosureSEC source: 0001437749-23-007564 · rdgdoc.xml · nonDerivative · entry 3 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,850 F3 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 23:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option · Derivative | 938 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-007564 · rdgdoc.xml · derivative · entry 4 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 938 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of September 15, 2022. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 23:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $20.64 | $206,400.00 |
DisclosureSEC source: 0001437749-23-007564 · rdgdoc.xml · nonDerivative · entry 2 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,160 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.47 to $20.76, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 23:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 938 | $2.06 | $1,932.28 |
DisclosureSEC source: 0001437749-23-007564 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2023 Filed Mar 10, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 31 | $22.95 | $711.45 |
DisclosureSEC source: 0001437749-23-006042 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,222 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,576 | $22.75 | $35,854.00 |
DisclosureSEC source: 0001437749-23-005438 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,253 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 117 | $21.47 | $2,511.99 |
DisclosureSEC source: 0001437749-23-004430 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,829 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 34,295 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000815 · rdgdoc.xml · derivative · entry 2 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,295 Underlying: Common Stock · 34,295 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 34,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000815 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,946 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation. Read SEC document |
| December 22, 2022 Filed Dec 24, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 528 | $17.55 | $9,266.40 |
DisclosureSEC source: 0001437749-22-029734 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,651 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 52 | $19.93 | $1,036.36 |
DisclosureSEC source: 0001437749-22-028235 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,179 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 22, 2022 Filed Nov 24, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 121 | $20.20 | $2,444.20 |
DisclosureSEC source: 0001437749-22-028059 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,231 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 00:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 569 | $21.91 | $12,466.79 |
DisclosureSEC source: 0001437749-22-023077 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,352 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 51 | $23.44 | $1,195.44 |
DisclosureSEC source: 0001437749-22-021728 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,921 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 16, 2022 Filed Aug 19, 2022 00:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 116 | $24.81 | $2,877.96 |
DisclosureSEC source: 0001437749-22-020999 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,972 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 14, 2022 Filed Aug 17, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-020749 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,088 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| July 29, 2022 Filed Aug 3, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 299 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-018509 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,854 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| July 17, 2022 Filed Jul 20, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-017382 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,555 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| July 03, 2022 Filed Jul 7, 2022 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 394 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-016769 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,193 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| June 24, 2022 Filed Jun 29, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 456 | $15.95 | $7,273.20 |
DisclosureSEC source: 0001437749-22-016098 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,799 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 19, 2022 Filed Jun 22, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 418 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-015534 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,255 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| June 05, 2022 Filed Jun 8, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 419 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-014537 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,837 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| May 27, 2022 Filed Jun 2, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 43 | $14.53 | $624.79 |
DisclosureSEC source: 0001437749-22-014060 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,418 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 22, 2022 Filed May 25, 2022 00:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 448 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-013466 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,461 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 125 | $12.32 | $1,540.00 |
DisclosureSEC source: 0001437749-22-012844 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,013 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 22, 2022 Filed Mar 25, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 551 | $23.06 | $12,706.06 |
DisclosureSEC source: 0001437749-22-007141 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,138 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 56 | $23.78 | $1,331.68 |
DisclosureSEC source: 0001437749-22-005227 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,324 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 23,365 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-005778 · rdgdoc.xml · derivative · entry 2 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,365 Underlying: Common Stock · 23,365 shares Expires not disclosed F3 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F3 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F3 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 23,365 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-005778 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,745 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2022 compensation. F2 · balance_after: The amount represented in Column 5 of Table I reflects the amount of securities beneficially owned by the reporting person as of the transaction date reported herein. It does not give effect to the transaction reported by the reporting person on the Form 4 filed by the reporting person on March 3, 2022. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 695 | $26.57 | $18,466.15 |
DisclosureSEC source: 0001437749-22-003759 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,380 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 07, 2022 Filed Jan 12, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 47 | $30.75 | $1,445.25 |
DisclosureSEC source: 0001437749-22-000744 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,075 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 07, 2022 Filed Feb 18, 2022 01:26 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 47 | $30.75 | $1,445.25 |
DisclosureSEC source: 0001437749-22-003761 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,075 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F2 · acquired: On January 11, 2022, the reporting person filed a Form 4 which inadvertently reported in Column 4 of Table I that the sale to cover transaction was an acquisition of securities rather than a disposition of securities. In fact, as reported in this amendment, the reporting person disposed of those shares. Read SEC document |
| December 22, 2021 Filed Dec 24, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 310 | $38.49 | $11,931.90 |
DisclosureSEC source: 0001437749-21-029225 · rdgdoc.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,122 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.